LifeStance Health Group, Inc. (NASDAQ:LFST) Forecasted to Post Q2 2022 Earnings of ($0.02) Per Share

LifeStance Health Group, Inc. (NASDAQ:LFSTGet Rating) – Analysts at Jefferies Financial Group boosted their Q2 2022 EPS estimates for shares of LifeStance Health Group in a research report issued on Tuesday, May 10th. Jefferies Financial Group analyst S. Wissink now expects that the company will post earnings of ($0.02) per share for the quarter, up from their prior forecast of ($0.03). Jefferies Financial Group also issued estimates for LifeStance Health Group’s Q3 2022 earnings at ($0.01) EPS, FY2022 earnings at ($0.22) EPS, Q1 2023 earnings at $0.01 EPS, Q3 2023 earnings at $0.02 EPS, FY2023 earnings at $0.06 EPS and FY2024 earnings at $0.17 EPS.

LifeStance Health Group (NASDAQ:LFSTGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). LifeStance Health Group had a negative net margin of 49.60% and a negative return on equity of 22.40%. The business had revenue of $203.10 million for the quarter, compared to analysts’ expectations of $191.47 million. The business’s revenue was up 41.9% on a year-over-year basis.

Several other analysts also recently weighed in on the company. The Goldman Sachs Group cut their price target on LifeStance Health Group from $15.00 to $10.00 and set a “neutral” rating on the stock in a research note on Monday, March 21st. UBS Group downgraded LifeStance Health Group from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $19.00 to $10.00 in a report on Thursday, March 17th. Finally, Zacks Investment Research upgraded LifeStance Health Group from a “sell” rating to a “hold” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.00.

LFST stock opened at $6.79 on Thursday. LifeStance Health Group has a fifty-two week low of $5.43 and a fifty-two week high of $29.81. The business’s 50 day moving average price is $9.00 and its two-hundred day moving average price is $9.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.28 and a current ratio of 2.28. The company has a market capitalization of $2.54 billion and a price-to-earnings ratio of -6.35.

In other news, CFO Jesse Michael Bruff sold 18,401 shares of the business’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $7.92, for a total transaction of $145,735.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Kevin Michael Mullins sold 46,283 shares of the company’s stock in a transaction on Wednesday, April 20th. The shares were sold at an average price of $10.68, for a total value of $494,302.44. Following the completion of the transaction, the insider now directly owns 5,669,472 shares in the company, valued at approximately $60,549,960.96. The disclosure for this sale can be found here.

Several hedge funds and other institutional investors have recently modified their holdings of LFST. Bank of America Corp DE acquired a new position in shares of LifeStance Health Group in the second quarter valued at about $200,000. SG Americas Securities LLC purchased a new position in shares of LifeStance Health Group in the third quarter valued at approximately $173,000. New York State Common Retirement Fund purchased a new position in shares of LifeStance Health Group in the third quarter valued at approximately $470,000. Deutsche Bank AG purchased a new position in LifeStance Health Group during the third quarter worth approximately $403,000. Finally, Principal Financial Group Inc. increased its stake in LifeStance Health Group by 1.8% during the third quarter. Principal Financial Group Inc. now owns 2,249,761 shares of the company’s stock worth $32,622,000 after acquiring an additional 39,594 shares during the last quarter. Hedge funds and other institutional investors own 80.71% of the company’s stock.

About LifeStance Health Group (Get Rating)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

Featured Stories

Earnings History and Estimates for LifeStance Health Group (NASDAQ:LFST)

Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.